LumiraDx at ECCMID 2021: Performance Data presented on the use of the LumiraDx Platform with LumiraDx SARS-CoV-2 Ag and Ab Test

Data Supports Use of LumiraDx SARS-CoV-2 Ag Test with Asymptomatic Patients* and LumiraDx SARS-CoV-2 Antibody Test Achieving WHO Requirements** for Diagnostic Performance

London, UK – July 9, 2021 – LumiraDx today presented data supporting the use of its SARS-CoV-2 Ag Test for asymptomatic adults and children* as well as data from an independent study demonstrating the SARS-CoV-2 Antibody Test meets the WHO performance requirements** for diagnostic sensitivity and specificity and is user friendly. The results are being presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.

“The LumiraDx SARS-CoV-2 Ag Test combines performance with speed, without compromising a high sensitivity of detection,” said Dr Jayne Ellis PhD, LumiraDx Head of Medical and Clinical Affairs. “With this additional data showing virus detection in asymptomatic patients*, there are even more use cases for our microfluidic test in helping to address the ongoing pandemic. Taken with our recent results demonstrating the test is able to detect the currently circulating variants of concern, LumiraDx is implementing fast and accurate testing at events, schools and workplaces, in support of safe and effective reopening of society.”

Dr Lennart Friis-Hansen, M.D., Clinical Associate Professor in the Department of Clinical Biochemistry at Copenhagen University Hospital, Bispebjerg and Frederiksberg, who will be sharing results from his study on the SARS-CoV-2 Antibody Test commented, “The high sensitivity and specificity mean that LumiraDx’s COVID-19 Antibody test will be a useful tool in detecting the presence of SARS-CoV-2 antibodies. The availability of a high performing SARS-CoV-2 Ab Test is especially important as antibody detection indicates prior infection and can be useful for infection surveillance.”

Details of Poster Presentations:

Title: An evaluation of the detection of SARS-CoV-2 antigen in a cohort of symptomatic and asymptomatic patients: Report from the evaluation of SKUP (Report number 2021/124 www.SKUP.org)
Poster: 4814
Presenter: Lucy Lehane, Medical Affairs Manager, LumiraDx\

Title: Performance of a microfluidic, immunofluorescence point-of-care SARS-CoV-2 Ag Test For detection for COVID-19 infection in asymptomatic adults and children
Poster: 4917
Presenter: Dr Jayne Ellis , Head of Medical and Clinical Affairs, LumiraDx

Title: A commercially available SARS-CoV-2 Antibody Test is well suited for clinical use
Poster: 4955
Presenter: Lennart Friis-Hansen, M.D., Clinical Associate Professor in the Department of Clinical Biochemistry at Copenhagen University Hospital, Bispebjerg and Frederiksberg

During the conference, ECCMID attendees can learn more about LumiraDx and meet with the team by visiting the company’s Virtual Booth accessed from the ECCMID Portal.

About LumiraDx

LumiraDx was founded in 2014 by a group of entrepreneurs: Ron Zwanziger, our Chairman and Chief Executive Officer; Dave Scott, Ph.D., our Chief Technology Officer; and Jerry McAleer, Ph.D., our Chief Scientist, who have a successful track record in building and scaling diagnostics businesses over three decades, including at companies such as Medisense, Inc., Inverness Medical Technology Inc. and Alere Inc. The company has raised approximately $1 Billion through debt and equity from institutional and strategic investors including the Bill & Melinda Gates Foundation, Morningside Ventures, U.S. Boston Capital Corporation and Petrichor Healthcare Capital Management. Based in the UK, with primary R&D and manufacturing operations in Stirling, Scotland and San Diego, CA, U.S., and supported by its worldwide affiliates to provide access in all major markets, LumiraDx has over 1200 employees worldwide.

Further information on LumiraDx and our SARS-CoV-2 product offerings visit available at lumiradx.com

*LumiraDx SARS-CoV-2 Ag Test has achieved CE Mark for asymptomatic individuals but has not yet been approved for this use case in the US.

**https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1